NCT06448793View on ClinicalTrials.gov

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Not yet recruitingOBSERVATIONAL
Enrollment

55

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Approved Non-small Cell Lung Cancer (NSCLC) therapies

As prescribed by treating physician

Trial Locations (1)

Unknown

Evidera, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06448793 - Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments | Biotech Hunter | Biotech Hunter